The PertADO Geneva Trial

Learn more about:
Related Clinical Trial
Pertussis Acellular Vaccine Adjuvanted With TQL1055 Seroprevalence of Pertussis Among Healthy Children and Adolescents in Kazakhstan A Multi-center Study to Determine the Prevalence and Influence of Pertussis on Subacute Cough in Shenzhen A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in Shenzhen Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years Maternal Pertussis Wholecell Responses Adacel® Booster Vaccination for CMI Assay Development Pathogenic Bordetella Rapid Detection 5-year Follow-up After a Single Dose Acellular Pertussis Vaccination Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly CD8 Reactivity to Microorganisms in Blood and Breast Milk Testing the Use of Prompts to Increase Adolescent Immunization Rates Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age Pilot Study Freeze and Transport Immune Cells Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants Immunogenicity and Safety of Sanofi Pasteur’s Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Pentavalent DTaP-Hep B-IPV DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants Evaluation of an Infant Immunization Encouragement Program in Nigeria A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ How Does the Clinical Tool ‘What’s Going Around’ Affect Clinical Practice Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs Immunology of Non-specific Effects of Vaccine Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth Immunogenicity and Safety of Pentaxim in South African Infants Immunogenicity and Safety of Pentaxim™ in an Indian Population Boostrix® Pregnancy Registry Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants Montelukast for Persistent Cough in Young People and Adults Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ Database Surveillance Safety Study of PENTACEL® Vaccine A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject A Study to Assess the Immunogenicity and Safety of GSK Biologicals’ Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting Protecting Pregnant Women From Infectious Diseases A Study to Assess the Safety of Adacel® Vaccine Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV Immunogenicity and Safety of Adacel Polio Vaccine Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® Confirmatory Study of BK1310 in Healthy Infants Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) Influence of BCG on TDaP-IPV Vaccination A Phase IV Study to Assess the Safety of EupentaTM Inj Phase I Clinical Trial in Healthy Children The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) Maternal Antibody in Milk After Vaccination Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Safety and Immune Response of Different Pediatric Combination Vaccines. Sanofi Pasteur’s Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China. Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) Tdap Vaccination for Infant Caregivers Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® TDAP Safety in Pregnant Women Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine The Safety of Boostrix Following Routine Immunization of Pregnant Women Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Tdap Vaccine in Post-Partum Women Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Post Marketing Surveillance for ADACEL™ in South Korea Vouchers to Promote Tdap Vaccination Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1) Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibodies Response After a Single Dose of Tdap Vaccine in Thai Pregnant Women Viaskin Pertussis Vaccine Trial Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine The Feasibility of Pertussis Immunization in a Canadian Emergency Department Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012) Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines Assessing Contacts’ Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines Maternal Tdap Immunization in Guatemala Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 – 12 Years Old The PertADO Geneva Trial Study of Adacel® Vaccine Administered to Persons 10 Years of Age Pertussis Immunization During Pregnancy & HIV Infection Observational Study Describing the Immune Profile Induced By Pertussis Vaccines Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare Professionals Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Pertussis and Meningitis C Concomitant Vaccination in Adolescents Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine 2-year Follow-up After a Single Dose Acellular Pertussis Vaccination Pertussis Vaccine in Healthy Pregnant Women Pertussis Vaccination in Pregnant Women A Study Exploring Whooping Cough Protection in Children and Adults Immunising Mums Against Pertussis 3 3-year Follow-up After a Single Dose Acellular Pertussis Vaccination A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine Optimising the Timing of Whooping Cough Immunisation in MUMs Bordetella Pertussis Colonisation Challenge Study Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines Gambia Pertussis Study (GaPs) A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants Pertussis Infection in Adolescents and Adults With Prolonged Cough Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants Pertussis (Tdap) Vaccination in Pregnancy

Brief Title

The PertADO Geneva Trial

Official Title

A Phase II Randomized, Observer-blind Controlled Pilot Study to Compare the Safety and Immunogenicity of Acellular Pertussis Vaccines Including Chemically or Genetically-detoxified Pertussis Toxin in Adolescents Aged 11-15 Years Previously Immunized With Acellular Pertussis Vaccines

Brief Summary

      This is a phase II, randomized double-center, and observer-blind controlled pilot vaccine
      trial in 11 to 15 years old healthy subjects to assess the immunogenicity of the genetically
      detoxified pertussis toxin (rPT) included in a novel acellular pertussis vaccine (Pertagen®)
      manufactured by BioNet-Asia when delivered by the intramuscular route to adolescents
      previously primed and boosted with chemically-detoxified PT, along with Td-pur® and in
      comparison with that of Boostrix® dTpa.

      At Day 0, eligible volunteers will undergo a venous bleed for the determination of baseline
      values and enter the randomization scheme, being allocated to one of two groups: A (Pertagen®
      + Td-pur®), B (Boostrix® dTpa).

      Randomized participants will receive one dose of Pertagen® and Td-pur® (Group A) or 1 dose of
      Boostrix® dTpa (Group B) by intramuscular injection in the deltoid. All subjects will be
      observed in the Plateforme de Recherché Pédiatrique for 30 minutes after immunization.

      Post-immunization local and systemic reactions will be followed up for 7 days after
      immunization. Adverse events will be followed for 28 days after immunization.

      At Day 28, a second visit (study end visit) will take place for safety evaluation and blood
      draw for immunogenicity evaluation.

      Blood draws performed on Day 0 (Baseline) and Day 28 will be used to evaluate immune response
      to study vaccines.

      The primary statistical analysis will be performed with visit 2 (Day 28) data to compare the
      immunogenicity and safety of one dose of Pertagen®, given simultaneously with Td-pur®, to
      those elicited by Boostrix® dTpa.
    

Detailed Description

      A significant increase of pertussis incidence is reported in a growing number of countries.
      This resurgence is considered as resulting from the limited durability of aP-vaccine-induced
      immunity and is associated with increased mortality in young infants and morbidity at all age
      groups. As the pertussis immunity acquired through immunization or infection is short-lived,
      its maintenance or reactivation requires repeat boosting at regular time points. Thus, novel
      strategies capable of reactivating pertussis immunity in older children, adolescents or
      adults, including pregnant women, are needed.

      A puzzling observation is that the efficacy of current acellular pertussis vaccines (which
      contain chemically-detoxified pertussis toxoid (PT)) is higher in infants and children than
      adolescents, in whom vaccine efficacy is limited and rapidly wanes. This may derive - at
      least in part - from priming and repeat immunizations with acellular vaccines containing
      chemically-detoxified PT and thus induction of antibodies specific of the
      chemically-detoxified PT but unable to efficiently recognize the native PT expressed by B.
      pertussis.

      The development of optimized acellular pertussis vaccines should thus include antigens with a
      similar immunogenicity profile as native PT but deprived of its toxic properties. This is
      best achieved through the genetic rather than chemical detoxification of PT, which results in
      both nontoxic and immunogenic PT.

      Clinical studies have shown the good tolerability profile and the superior immunogenicity
      profile of acellular pertussis vaccines including genetically-detoxified PT (rPT) in adults
      and adolescents previously primed with whole-cell pertussis (wP) vaccines. As whole-cell
      vaccines express native PT, whether the superior immunogenicity of rPT will be observed in
      adolescents/adults previously primed with acellular pertussis vaccines containing
      chemically-detoxified PT is of key importance.

      This is a phase II randomized, observer-blind controlled study to compare the safety and
      immunogenicity of acellular pertussis vaccines including chemically or genetically-detoxified
      pertussis toxin in adolescents aged 11-15 years. The primary objective is to assess the
      immunogenicity of the genetically detoxified pertussis toxin (rPT) included in a novel
      acellular pertussis vaccine (Pertagen®) when delivered by the intramuscular route to
      adolescents previously primed and boosted with chemically-detoxified PT, along with Td-pur®
      and in comparison with that of Boostrix® dTpa. The secondary objectives are (1) to assess
      safety of Pertagen® when administered with Td-pur® to adolescents as compared to Boostrix®
      dTpa and (2) to assess the humoral responses elicited by Pertagen® when administered with
      Td-pur® as compared to Boostrix® dTpa.

      In this study, exploratory immunological measures will also be performed (pending sufficient
      or additional funding). These are anticipated to include:

        -  The assessment of antibody titers to specific neutralizing and non-neutralizing epitopes
           of PT, by competitive ELISA, before and after (Day 28) boosting with Pertagen® and
           Boostrix® dTpa.

        -  To assess cellular responses to PT before and after boosting with Pertagen® and
           Boostrix® dTpa.

        -  To assess the frequency and phenotype of PT-specific memory B cell responses (as
           compared to tetanus toxoid) before and after boosting with Pertagen® or Boostrix® dTpa
           (i.e. at Day 0 and Day 28).

        -  To characterize changes in cellular responses following boosting with Pertagen® or
           Boostrix® dTpa

      Three vaccines will be used in the study. The BioNet-Asia study vaccine (Pertagen®), Td-pur®
      (Novartis/GSK) which will be concomitantly administered with the study vaccine, and the
      control Boostrix® dTpa.

      The investigational product Pertagen® will be manufactured, labeled, packaged and released
      for clinical use by BioNet-Asia, in accordance with the requirements of Good Manufacturing
      Practices.Both Td-pur® and Boostrix® dTpa vaccines used in this study are commercially
      available in Switzerland and will be purchased for the study. One batch of each vaccine will
      be used for the entire study.

      All vaccines are presented in 0.5 mL pre-filled syringes to be administered by intramuscular
      injection. The study vaccine Pertagen® and Boostrix® dTpa will be administered in the
      non-dominant deltoid. If applicable, Td-pur® will be administered in the contralateral
      deltoid.

      At Day 0, eligible subjects will be randomized in a 1:1 ratio into one of the following
      vaccine groups:

      Group 1 Pertagen® and Td-pur 30 volunteers Group 2 Boostrix® dTpa 30 volunteers

      A randomization list containing subject numbers and vaccine group assignments will be
      established and provided to the clinical investigators. Each participant will be immunized
      according to the vaccine group assignment. At study site, the Principal investigator will
      designate the blinded and unblinded teams in order to keep the observer-blind design of the
      study.

      The unblinded personal will be responsible for study vaccine preparation, handling, storage
      and accountability, and immunization.

      The blinded team will be responsible for assessing adverse events. The laboratory staff
      performing the immunological assays will also be blinded. After vaccination, volunteers will
      be observed for 30 minutes at study site for any immediate post-immunization reactions.
      Reactogenicity and safety will be assessed during study visits at the clinical trial unit
      (CTU) on Day 0 and Day 28 after immunization. At Day 0 (Visit 1, vaccination day), a Diary
      Card will be distributed to study volunteer to record post-immunization local and systemic
      reactions and adverse events. At Day 28 (Visit 2), investigator will reconcile and transcribe
      the Diary Card information in the CRF. Post-immunization local and systemic reactions will be
      collected and monitored for 7 days after vaccination. All adverse events, including SAEs,
      will be collected and monitored for 28 days after vaccination (until Visit 2).

      Study participants will be contacted by phone at Day 7 to confirm that adverse reactions have
      subsided. Should this not be the case, an unscheduled visit will be considered as
      appropriate.

      All AEs and SAEs occurring within the 28 days following treatment and observed by the
      Investigator or reported by the volunteer, whether or not attributed to study intervention,
      will be recorded in the CRF. All AEs that result in a volunteer's withdrawal from the study
      will be followed up until a satisfactory resolution occurs, or until a non-study related
      causality is assigned (if the volunteer consents to this).

      Sample size calculation This is a phase II randomized, observer-blind controlled pilot study
      to compare the safety and immunogenicity of acellular pertussis vaccines including chemically
      or genetically-detoxified pertussis toxin in adolescents previously immunized with acellular
      vaccines. The sample size for this study is based on clinical and practical considerations
      and not on a formal statistical power calculation. Where applicable, 2-sided test at the 5%
      significance level will be utilized with no multiplicity adjustment. P-values will be
      considered exploratory only. Sixty volunteers will be randomized in total, with 30 in each
      group.

      Safety analysis The safety analysis will include all randomized subjects who have received a
      dose of study vaccine.

      The overall percentage of subjects with at least one spontaneously reported adverse event,
      with date of onset up to 28 days after vaccination will be tabulated with exact 95%
      confidence intervals, by type of adverse event; by severity; and by causality. They will be
      displayed by vaccine group as both frequencies and percentages on the ITT data set.

      All reported adverse events that start post-vaccination will be tabulated. If a given disease
      is already reported as ongoing at the first visit on the medical history pages, it will be
      counted and tabulated as a vaccine emergent adverse event only if it worsens after the
      immunization with the study vaccine.

      Serious adverse events and discontinuation due to adverse event(s) will be described in
      detail by vaccine group.

      Immunogenicity analyses The primary immunogenicity endpoint will assess the immune response
      to Pertagen® - as compared to Boostrix® dTpa - by measuring the Day 28 geometric mean
      concentration (GMC) of neutralizing antibodies to PT.

      The other immunogenicity end-points include:

        -  GMCs of PT, FHA, tetanus and diphtheria-toxoid specific IgG antibodies measured by ELISA

        -  Seroresponse rates of PT, FHA, tetanus and diphtheria-toxoid specific IgG antibodies
           measured by ELISA

        -  Reverse cumulative distribution curves of PT neutralizing antibodies, and of PT, FHA,
           tetanus and diphtheria-toxoid IgG antibodies

        -  To compare PT-specific responses elicited by Pertagen® in adolescents previously
           immunized (this study) or not (BioNet Phase II/III TDA202) by acellular pertussis
           vaccines The following descriptive statistics will be provided for each variable: number
           of subjects, percentages, mean, geometric mean, standard deviation, median, minimum,
           maximum, and range.

      Quality Control and Quality Assurance Procedure Approved site-specific SOPs will be used at
      clinical and laboratory sites. Monitoring will be performed according to ICH Good Clinical
      Practice (GCP) by the Centre de Recherche Clinique (CRC) of the University Hospital of
      Geneva. Following a Monitoring Plan and written SOPs, the monitors will verify that the
      clinical trial is conducted and data are generated, documented and reported in compliance
      with the protocol, GCP and the applicable regulatory requirements. The CTU will provide
      direct access to all trial-related source data, documents and reports for the purpose of
      monitoring and inspection by local and regulatory authorities.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Geometric mean concentration (GMC) of neutralizing antibodies to PT

Secondary Outcome

 Safety endpoints evaluated by solicited local and systemic reactions and unsolicited adverse events (AEs)

Condition

Pertussis

Intervention

Pertagen® aP + Td-pur®

Study Arms / Comparison Groups

 Arm 1: Pertagen® aP + Td-pur®
Description:  BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

60

Start Date

October 27, 2016

Completion Date

March 9, 2017

Primary Completion Date

March 9, 2017

Eligibility Criteria

        Inclusion criteria

        The volunteer must satisfy the following criteria to be eligible for the study:

          1. Has provided written informed consent before enrollment;

          2. Male or female, ages 11-15 years (inclusive) at the time of enrollment;

          3. With documented history of acellular pertussis immunization (5 doses);

          4. Free of clinically significant health problems, as determined by pertinent medical
             history and clinical examination at study screening;

          5. Non-pregnant, non-lactating female :

               -  for female subjects who had menarche, this implies a negative urinary pregnancy
                  test at enrolment;

               -  If sexually active, female subjects must be willing to use reliable birth control
                  measures for 1 month after vaccination;

          6. Able to attend all scheduled visits and to understand and comply with the study
             procedures; Exclusion criteria

        The volunteer may not enter the study if any of the following apply:

          1. Prior dTpa immunization within the last 5 years or prior dT immunization within the
             last 2 years, or any other investigational vaccine likely to impact on interpretation
             of the trial data, as judged by the Principal Investigator;

          2. Suspected or confirmed pertussis infection within the last 10 years or documented
             pertussis infection in a household member within the last 10 years;

          3. History of severe local or systemic reactions to any vaccination or a history of
             severe allergic reactions;

          4. Known hypersensitivity or allergy to diphtheria, tetanus, or pertussis vaccine
             (including excipients);

          5. Receipt of investigational product up to 30 days prior to enrollment or ongoing
             participation in another interventional clinical trial;

          6. Receipt of licensed vaccines within 30 days of planned study immunization or ongoing
             participation in another clinical interventional trial;

          7. Acute or chronic, clinically significant psychiatric, hematologic, pulmonary,
             cardiovascular, or hepatic or renal functional abnormality as determined by the
             Investigator based on medical history, physical exam;

          8. Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection, asplenia, cytotoxic therapy in the
             previous 5 years, and/or diabetes;

          9. Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding
             febrile seizures as a child;

         10. Has a known history of Guillain-Barré Syndrome;

         11. Has an active malignancy or recent (<10 years) history of metastatic or hematologic
             malignancy;

         12. Suspected or known alcohol and/or illicit drug abuse within the past 5 years;

         13. Pregnant or lactating female, or female who intends to become pregnant during the
             study period;

         14. Administration of immunoglobulins and/or any blood products within the 120 days
             preceding study entry or planned administration during the study period;

         15. Receipt of chronic (>14 days) immunosuppressants or other immune modifying drugs
             within 6 months of study entry:

               -  For corticosteroids, this will mean prednisone or equivalent ≥0.5 mg/kg/day,

               -  Intranasal and topical steroids are allowed;

         16. Any other significant finding that, in the opinion of the investigator, would increase
             the risk of the individual's having an adverse outcome by participating in this study.

        Temporary exclusion criteria at the time of randomization

        The following criteria constitute contraindications to administration of vaccine at that
        point in time; if any one of these occurs at the time scheduled for randomization, the
        subject may be randomized at a later date without the need for re-screening, at the
        discretion of the Investigator, or withdrawn at the discretion of the Investigator:

          -  Acute disease at the time of randomization. (Acute disease in the context of this
             trial is defined as the presence of a moderate or severe illness with or without
             fever.) The vaccine/placebo can be administered to persons with a minor illness such
             as mild upper respiratory tract infection with or without low-grade febrile illness,
             i.e. temperature of ≤37.5°C;

          -  Body temperature ≥38°C within 3 days of the intended vaccination;

          -  Any other significant finding that, in the opinion of the investigator, would
             temporarily increase the risk of the individual's having an adverse outcome by
             participating in this study.
      

Gender

All

Ages

11 Years - 15 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Claire-Anne Siegrist, MD, , 

Location Countries

Switzerland

Location Countries

Switzerland

Administrative Informations


NCT ID

NCT02946190

Organization ID

CER 2016-00500


Responsible Party

Sponsor-Investigator

Study Sponsor

Siegrist Claire-Anne

Collaborators

 BioNet-Asia Co., Ltd.

Study Sponsor

Claire-Anne Siegrist, MD, Principal Investigator, Center for Vaccinology, Medical Faculty (UNIGE) and University Hospitals of Geneva (HUG), CMU


Verification Date

May 2017